WALTLOO, PRETORIA, Nov 2, 2020 — Chemical Process Technologies Pharma (CPT Pharma), a relative newcomer to the field of generic active pharmaceutical ingredients (API) production, has been granted a licence by the South African Health Products Regulatory Authority (SAHPRA) to manufacture APIs for human medicine on 28 August 2020.
South Africa currently imports the vast majority of the APIs used to formulate medicines in local plants, mainly from manufacturers in India and China. This dependence has at times led to import and distribution problems. The granting of the licence signals a significant move forward for the South African pharmaceutical industry. ‘We are honoured as a company at being able to take the lead in advancing the South African pharmaceutical industry through obtaining this licence. While we appreciate the milestone, we acknowledge that there’s still a lot of work to be done in this space,’ says Dr. Hannes Malan, Managing Director at CPT.